Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication

Circulation

Volumn 95, Issue 9, 1997, Pages 2298-2302

  Belch, J J F ^a   Bell, P R F ^h   Creissen, D ^b   Dormandy, J A ^c   Kester, R C ^d   McCollum, R D ^a   Mizushima, Y ^e   Ruckley, C V ^h   Scurr, J H ^f   Wolfe, J H N ^g  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Advisory Services Ltd   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f MIDDLESEX HOSPITAL   (United Kingdom)

^g ST MARY S HOSPITAL   (United Kingdom)

^h NONE

Author keywords

claudication; peripheral vascular disease; prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; AS 103; BLOOD CLOTTING FACTOR 8; INTRALIPID; LIPOPROSTAGLANDIN E1; PLACEBO; PRODRUG; PROSTAGLANDIN E1 DERIVATIVE; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; INTERMITTENT CLAUDICATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREADMILL EXERCISE; WALKING;

EID: 0030939880     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.9.2298     Document Type: Article

References (22)

1. Leng GC, Fowkes FGR. The epidemiology of peripheral arterial disease. Vasc Med Rev. 1993;4:5-18.
2. Fowkes FGR, Housley E, Cawood EHH. Macintyre CCA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384-391.
3. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials. 1965-1985. Br J Clin Pharmacol. 1988;26: 569-576.
4. Duprez D, Clement DL. Medical treatment of peripheral vascular disease: good or bad? Eur Heart J. 1992;13:149-151.
5. CPMP Efficacy Working Party. Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Chronic Peripheral Arterial Occlusive Disease. London, UK: The European Agency for the Evaluation of Medicinal Products: December 1994 (revised November 1995).
6. Vane JR. The release and fate of vasoactive hormones in the circulation. Br J Pharmacol. 1968;35:209-214.
7. Belch JJF, McKay A, McArdle B, Lowe GDO, Pollock JG, Leiberman P, Forbes CD, Prentice CRM. A double blind study of the effect of prostacyclin infusion in severe peripheral vascular disease. Lancet. 1983;8320:315-317.
8. Belch JJF. The role of the white blood cell in arterial disease. Blood Coagul Fibrinolysis. 1990;1:183-192.
9. Sinzinger H. Prostaglandins in ischaemic peripheral vascular disease. In: Therapeutic Applications of Prostaglandis. Vane J, O'Grady J, eds. London, UK: Edward Arnold; 1993:209-218.
10. 1-Infusionsbehandlung bei Patienten mit arterieller Verschlusskrankheit im Stadium IIb. In: Heidrich H, Bohme H, Rogatti W, eds. Prostaglandin EI: Wirkungen und therapeutische Wirksamkeit. Berlin, Germany: Springer Verlag; 1988: 103-111.
11. 1 versus pentoxifylline in patients with intermittent claudication. In: Diehm C, Sinzinger H, Rogatti E, eds. Prostaglandlin EI: New Aspects of Pharmacology, Metabolism and Clinical Efficacy. Heidelberg, Germany: Springer Verlag; 1991:101-108.
12. Mizushima Y. Lipo-prostaglandin preparations. Prostaglandins Leukot Essent Fatty Acids. 1991;42:1-6.
13. Pendler JH, Romero A. Liposomes as drug carriers. Life Sci. 1977;20:1109-1120.
14. Bundgarrd H, Hansen AB, Kofod H, eds. Optimization of Drug Delivery. Copenhagen, Denmark: Munksgaard; 1982.
15. 1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol. 1983;35: 666-667.
16. Mizushima Y. Application of lipid microspheres for targeting therapy. J Bioact Compat Polymer. 1988;3:148-156.
17. Davis S, Hadgraft J, Palin KJ. Pharmaceutical emulsions. In: Becher P, ed. Encyclopedia of Emulsion Technology. New York, NY: Marcel Dekker: 1985;3:159.
18. Fitzpatric FA, Liggett WP, Wynalda MA. Albumin-eicosanoid interactions: a model system to determine their attributes and inhibition. J Biol Chem. 1984;259:2722-2727.
19. 1 prodrug for targeting therapy. J Controlled Release. 1992;20:37-46.
20. Cho MJ. Reduced hydrolytic liability of epoprostenol in the presence of cationic micelles. J Pharmacol Sci. 1982;71:453-454.
21. Belch JJF, Zoma A, Richards I, Forbes CD, Sturrock RD. Vascular damage and factor VIII related antigen in the rheumatic diseases. Rheumatol Int. 1987;7:107-111.
22. Heidrich H, Cachovan M, Creutzig A, Rieger H, Trampisch HJ. Guidelines for therapeutic studies in Fontaine's stages II-IV peripheral arterial occlusive disease. Vasa. 1995;24:114-119.